TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21537858

Group type: EXPERIMENTAL
Intervention: Alfusosin, 10 mg/24 h for at least 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field at radiofrequencies, 30 min daily, 5 consecutive days per week for 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Alfusosin)
Number of subjects: 20
Study: 18264697

Group type: EXPERIMENTAL
Intervention: 40 mg MPH
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 17036477

Group type: EXPERIMENTAL
Intervention: Ginger-salt-partitioned moxibustion at Shenque (CV 8)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 82
Study: 12727767

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 236
Study: 11028700

Group type: EXPERIMENTAL
Intervention: Patients with vestibular labyrinth hypofunction
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonimpaired controls
Number of subjects: 15
Study: 9463116

Group type: EXPERIMENTAL
Intervention: Uric acid level in aqueous humor of patients with cataract
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Comparison between cataract patients and control group
Number of subjects: 32
Study: 1311351

Group type: EXPERIMENTAL
Intervention: sodium stibogluconate (20 mg of antimony per kilogram per day intravenously for 20 days)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ketoconazole (600 mg per day orally for 28 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 6707244

Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 21 mg methylphenidate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 10 mg and 21 mg methylphenidate
Number of subjects: 9
Study: 31241173

Group type: EXPERIMENTAL
Intervention: Imatinib (various doses)
Number of subjects: 132
Study: 30270576

Group type: EXPERIMENTAL
Intervention: High-fat meals
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Functional food meals
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard meals
Number of subjects: 37
Study: 27076578

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 24605819

Group type: EXPERIMENTAL
Intervention: Algal docosahexaenoic acid supplementation (600 mg day(-1) for 16 weeks)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Algal docosahexaenoic acid supplementation
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 22828535

Group type: EXPERIMENTAL
Intervention: Wound infiltration with levobupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paracetamol administration per rectally
Number of subjects: 120
Study: 20056639

Group type: EXPERIMENTAL
Intervention: Interactive, tailored computer instruction at baseline and four monthly lay health advisor counseling sessions
Number of subjects: 181

Group type: COMPARATOR
Intervention: Low-dose comparison group consisting of a culturally appropriate mammography screening pamphlet
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Combined intervention (computer program + lay health advisor)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 181
Study: 18019665

Group type: EXPERIMENTAL
Intervention: Obese individuals with insulin resistance
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Obese type 2 diabetics treated with metformin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (nonobese healthy individuals)
Number of subjects: 56
Study: 15668481

Group type: EXPERIMENTAL
Intervention: CCND1 A870G polymorphism (A allele)
Number of subjects: 1126
Study: 12973167

Group type: EXPERIMENTAL
Intervention: Social worker intervention for families of patients at high risk for decisional conflict
Number of subjects: 873
Study: 10770450

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 17
Study: 8681493

Group type: EXPERIMENTAL
Intervention: Mazapertine (5 to 50 mg over 7 days; n = 10)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mazapertine (20 or 30 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mazapertine (40 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mazapertine (incremental dosing)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (n = 3)
Number of subjects: 13
Study: 1920817

Group type: EXPERIMENTAL
Intervention: Ketanserin (KET) 40 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketanserin (KET) 40 mg + Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 20
Study: 6227244

Group type: EXPERIMENTAL
Intervention: megadose multi-vitamin/mineral supplement for 4 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo in identical form
Number of subjects: 24
Study: 31743334

Group type: EXPERIMENTAL
Intervention: Anti-OSP antibody responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibriocidal responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IgA anti-OSP in blood group O individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with endemic zone cohorts
Number of subjects: 0
Study: 29272357

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg orally twice daily for 12 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 15
Study: 26791028

Group type: EXPERIMENTAL
Intervention: Augmented repair
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonaugmented repair
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 25491391

Group type: EXPERIMENTAL
Intervention: MSC treatment in combination with everolimus and prednisolone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group receiving everolimus, prednisolone, and standard dose tacrolimus
Number of subjects: 70
Study: 22406532

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Niacin + PGD₂ receptor DP1 antagonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platelet-rich plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: COX inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platelet depletion, COX‐1 knockdown, COX‐2 deletion in mice
Number of subjects: 0
Study: 21054285

Group type: EXPERIMENTAL
Intervention: Vitamin D(2) 1,000 IU/d
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 17985420

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with MTX, sulfasalazine, and prednisone (Group 3)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with MTX and infliximab (Group 4)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Sequential monotherapy (Group 1)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Step‐up to combination therapy (Group 2)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 508
Study: 16283981

Group type: EXPERIMENTAL
Intervention: Less invasive radial artery harvesting (LIRAH)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Conventional radial artery harvesting (CRAH)
Number of subjects: 177
Study: 11896097

Group type: EXPERIMENTAL
Intervention: Postoperative hepatic arterial floxuridine combined with intravenous continuous‐infusion fluorouracil (chemotherapy arm)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control arm (no further therapy)
Number of subjects: 109
Study: 9860205

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional ventilatory support
Number of subjects: 40
Study: 7608809

Group type: EXPERIMENTAL
Intervention: Immunochemiluminometric assays (ICMA) for LH
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Immunochemiluminometric assays (ICMA) for FSH
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: GnRH stimulation test for LH
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: GnRH stimulation test for FSH
Number of subjects: 375

Group type: COMPARATOR
Intervention: Comparison of ICMA with immunofluorometric assay and radioimmunoassay
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: ICMA for LH
Number of subjects: 375
Study: 2122713

Group type: EXPERIMENTAL
Intervention: 10% Intralipid (IL) phospholipid, n = 5
Number of subjects: 11

Group type: COMPARATOR
Intervention: 20% Intralipid (IL) phospholipid, n = 6
Number of subjects: 11
Study: 373908

Group type: EXPERIMENTAL
Intervention: Adriamycin plus vincristine (AV)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: High-energy radiotherapy (RT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Additional chemotherapy (6 more cycles)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combined treatment modality
Number of subjects: 110
Study: 31095954

Group type: EXPERIMENTAL
Intervention: PPV plus IVB (1.25 mg bevacizumab)
Number of subjects: 224

Group type: COMPARATOR
Intervention: PPV plus sham
Number of subjects: 224
Study: 28114915

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive Behavior Therapy (TCBT)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Diagnosis specific group CBT
Number of subjects: 248
Study: 25851385

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard oxygen therapy (control)
Number of subjects: 155
Study: 22222299

Group type: EXPERIMENTAL
Intervention: Effervescent potassium calcium citrate (PCC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Citracal Petite (tablet formulation of calcium citrate)
Number of subjects: 15
Study: 21116175

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual activity (Control)
Number of subjects: 19
Study: 20214047

Group type: EXPERIMENTAL
Intervention: Serum insulin-like growth factor-1 (IGF-1) level
Number of subjects: 15
Study: 16901421

Group type: EXPERIMENTAL
Intervention: Carbamazepine or sodium valproate
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (80 healthy children)
Number of subjects: 51
Study: 15043351

Group type: EXPERIMENTAL
Intervention: Spinal orthosis for 6 months
Number of subjects: 0
Study: 11318769

Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1 : 80 000
Number of subjects: 195

Group type: COMPARATOR
Intervention: Lignocaine 2%
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1 : 160 000
Number of subjects: 195
Study: 9863095

Group type: EXPERIMENTAL
Intervention: Ginkgo leave concentrated oral liquor (GLC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7934188

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 2450612

Group type: EXPERIMENTAL
Intervention: Urovison
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Iopamiro
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Urovison, Hexabrix, Iopamiro
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low-osmolality contrast media
Number of subjects: 200
Study: 31754962

Group type: EXPERIMENTAL
Intervention: AA + P + ADT
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo + ADT
Number of subjects: 112
Study: 28117141

Group type: EXPERIMENTAL
Intervention: Coarse CAP
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fine CAP
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrafine CAP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Filtered medical air
Number of subjects: 50
Study: 25967848

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 24314422

Group type: EXPERIMENTAL
Intervention: Anterior chamber paracentesis (ACP) and medical treatment (group 1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Medical management alone (group 2)
Number of subjects: 54
Study: 20304541

Group type: EXPERIMENTAL
Intervention: Alar base cinch suture
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no cinch suture)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 19370729

Group type: EXPERIMENTAL
Intervention: Rehabilitation program based on treadmill training associated with auditory and visual cues
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rehabilitation protocol using cues not associated with treadmill
Number of subjects: 40
Study: 16838377

Group type: EXPERIMENTAL
Intervention: Therapeutic tape
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control tape
Number of subjects: 12
Study: 15589640

Group type: EXPERIMENTAL
Intervention: Transvenous cryoablation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 200
Study: 11247890

Group type: EXPERIMENTAL
Intervention: Patients with Crohn's disease
Number of subjects: 32
Study: 9236054

Group type: EXPERIMENTAL
Intervention: MF59 adjuvant with subunit influenza vaccine
Number of subjects: 1807

Group type: COMPARATOR
Intervention: Subunit influenza vaccine without MF59
Number of subjects: 1807
Study: 8314169

Group type: EXPERIMENTAL
Intervention: sustained-release bezafibrate 400 mg (n = 21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo (n = 19)
Number of subjects: 40
Study: 3518423

Group type: EXPERIMENTAL
Intervention: Tunneled subcutaneous catheters
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Catheters inserted over a guidewire
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall catheter colonization
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Catheter-associated bacteremia
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Catheters removed from febrile patients
Number of subjects: 88
Study: 30252723

Group type: EXPERIMENTAL
Intervention: Heat + antioxidant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat + placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No heat
Number of subjects: 0
Study: 27322154

Group type: EXPERIMENTAL
Intervention: Affective messaging intervention ('Pregnant Pause' video)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Cognitive messaging intervention ('Vaccines for a Healthy Pregnancy' video)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Comparison condition (receipt of the Influenza Vaccine Information Statement)
Number of subjects: 106
Study: 24802090

Group type: EXPERIMENTAL
Intervention: Five 1‐hr milieu communication teaching (MCT) sessions per week (daily treatment)
Number of subjects: 63

Group type: COMPARATOR
Intervention: One 1‐hr milieu communication teaching (MCT) session per week (weekly treatment)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Parental linguistic mapping measured after 6 months of treatment
Number of subjects: 63
Study: 22232129

Group type: EXPERIMENTAL
Intervention: Ringer-Lignocaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20507378

Group type: EXPERIMENTAL
Intervention: EMD+AB (enamel matrix derivative combined with autogenous bone)
Number of subjects: 40

Group type: COMPARATOR
Intervention: EMD (control)
Number of subjects: 40
Study: 17649651

Group type: EXPERIMENTAL
Intervention: Health promotion model intervention activities
Number of subjects: 2343
Study: 15982128

Group type: EXPERIMENTAL
Intervention: Emotional scenes presented parafoveally for 150-3000 ms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral scenes presented parafoveally for 150-3000 ms
Number of subjects: 0
Study: 12356338

Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11095258

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 122

Group type: COMPARATOR
Intervention: Endometrial surveillance alone
Number of subjects: 122
Study: 9456632

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with trigger points technique
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 243
Study: 1559737

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine lotion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine cream
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vehicle for ciclopirox olamine lotion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vehicle for ciclopirox olamine cream
Number of subjects: 26
Study: 4014092

Group type: EXPERIMENTAL
Intervention: Theophylline ethylenediamine (group 1, n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine sodium citrate (group 2, n = 8)
Number of subjects: 16
Study: 31056705

Group type: EXPERIMENTAL
Intervention: URC102 (1-30 mg single dose for Koreans, 1-10 mg single dose for Caucasians)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: URC102 (1-20 mg once-daily for 7 days for 44 Koreans)
Number of subjects: 54
Study: 29914413

Group type: EXPERIMENTAL
Intervention: CES-D 10 scale
Number of subjects: 2098
Study: 26456955

Group type: EXPERIMENTAL
Intervention: Lorazepam (LOR)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Group I (VPA vs PHT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Group II (LOR vs LEV)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: LOR and LEV combination
Number of subjects: 196
Study: 23944602

Group type: EXPERIMENTAL
Intervention: Static stretching (SS) program: three bouts of 2‐min SS of the plantar flexors, 6 days a week for 5 weeks.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 19
Study: 22342538

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 25 μg once daily
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 50 μg once daily
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 μg once daily
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 μg once daily
Number of subjects: 598

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 μg twice daily
Number of subjects: 598

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 598
Study: 20347836

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control (quiet relaxation time)
Number of subjects: 113
Study: 18343264

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Levetiracetam 5000 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 16166187

Group type: EXPERIMENTAL
Intervention: 7% CO2 inhalation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Compressed air (control)
Number of subjects: 30
Study: 12562571

Group type: EXPERIMENTAL
Intervention: Topiramate (25-600 mg/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 10555933

Group type: EXPERIMENTAL
Intervention: Celecoxib 50 mg twice/day
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice/day
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice/day
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice/day
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004
Study: 8916480

Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1750
Study: 31917607

Group type: EXPERIMENTAL
Intervention: Pitolisant (up to 20 mg/d over 12 weeks)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 31249709

Group type: EXPERIMENTAL
Intervention: Test adhesive (carbomer-based)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Reference adhesive (PVM/MA-based)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No adhesive
Number of subjects: 44
Study: 28708074

Group type: EXPERIMENTAL
Intervention: Wild nature video presentation
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Urban nature video presentation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Non-nature control video
Number of subjects: 220
Study: 26963851

Group type: EXPERIMENTAL
Intervention: Capsaicin (0.1 mg) injected into the intermetatarsal space
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo injected into the intermetatarsal space
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Capsaicin (0.1 mg)
Number of subjects: 58
Study: 24396284

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Ulcer stocking system
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Multi layer short stretch bandage
Number of subjects: 147

Group type: COMPARATOR
Intervention: Two layer short stretch bandages
Number of subjects: 147

Group type: COMPARATOR
Intervention: Unna boots
Number of subjects: 147
Study: 22141423

Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 213

Group type: COMPARATOR
Intervention: Community Control
Number of subjects: 213
Study: 19011440

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unmedicated patients (control)
Number of subjects: 15
Study: 15990749

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 481

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 481
Study: 12843167

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-20 mg/d)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (900-1200 mg/d)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined treatment (10 mg atorvastatin and 900 mg gemfibrozil)
Number of subjects: 44